CINGW | Cingulate Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0500 - 0.0800
52 Week Range	0.0500 - 0.0800
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	121,109
Average Volume	N/A
Shares Outstanding	168,152,528
Market Cap	13,452,202
Sector	Healthcare
Industry	Biotechnology
IPO Date	N/A

Valuation
Profitability
Growth
Health
P/E Ratio	-0.05
Forward P/E Ratio	N/A
EPS	-1.73
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	13
Country	USA
Website	CINGW

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.

CINGW's peers: BRTX, CADL, CMMB, EQ, GTBP, KZIA, PPBT, SABS, OKYO, CING, CELUW, NRSNW, EQRXW, DRMAW, NXGLW, GDTC, CVKD

*Chart delayed

Analyzing fundamentals for CINGW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CINGW Fundamentals page.

Watching at CINGW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on CINGW Technicals page.